Yana Reshetnyak is an inventor of the pHLIP^® technology and founder of the company. She is an expert in fluorescence imaging, membrane biophysics, oncology, inflammation, drug delivery and targeted therapies. Yana joined the Physics Department at the University of Rhode Island (URI) as an NSF Faculty Fellow in 2004, where she developed a Medical Physics program and served as a Director from 2010 to 2019. As a Professor, Yana has led her laboratory in the development of pHLIP^® technology and managed multi-million and multi-PI NIH and DoD grants for the last 17 years, leading to >60 pHLIP^®patents and patent applications. As pHLIP, Inc CEO and President since 2014, Yana has been leading company operations and financies, preclinical and IND-enabling studies, GMP manufacturing, clinical translation, IP development, strategic partnership and sublicensing. Yana has received URI Research and IP excellence Awards, the Maitland P. Simmons Memorial Research Award, the Gregorio   Weber   International   Competition   Award in Fluorescence, the Stefan Batory Foundation Award, Soros Awards, and a Wood/Whelan Fellowship from the International Union of Biochemistry and Molecular Biology.

[Employment effective January 1, 2021] Steven Wilcox has been a corporate lawyer at Ropes & Gray for his entire career, where he was made a partner in 1989. Steve has served as our outside counsel since our formation, and plans to join our company full time on January 1, 2021.  Steve founded Ropes & Gray’s Life Sciences Practice Group in 1997 and served as its Chair for many years, establishing one of the world’s largest and most respected Life Sciences practices. Steve has deep Life Sciences industry experience and relationships and a track record of completing complex BD transactions with Biotech, Pharma and Medical Device companies. Many of the world’s largest pharmaceutical and medical device companies have turned to Steve to be their lead counsel on their most important strategic transactions.  In addition, Steve has incorporated and helped venture-finance numerous start-ups, has helped take them public and/or sold them in successful exits.

Chief Financial and Operating Officer will join Company in Q4 2020

Oleg Andreev is Professor of Physics at the University of Rhode Island (URI) and Adjunct Professor at the Rhode Island Hospital, Radiation Oncology, Warren Alpert Medical School of Brown University. Prior to joining faculty at URI, Oleg has had industry experience as a Lead Scientist in a Harvard-based Startup. At URI, Oleg has led the Physics Department as its Chairman from 2013 to 2019. He served as a member of the Institutional Intellectual Property Committee for several years. Oleg is an inventor of the pHLIP^® technology and an expert in biochemistry, optics, imaging, cancer nanotechnology, and animal studies. He has about two decades of experience in the development of pHLIP^® imaging and therapeutic products, and is a co-author of about 60 pHLIP^® patents and patent applications. Oleg has received URI Research and IP excellence Awards, Outstanding Inventor Awards, and the Maitland P. Simmons Memorial Research Award.

[Employment effective 2021] David Wolfsohn is a Clinical Assistant Professor at  the Yale School of Medicine and a  managing partner at Connecticut Gastroenterology Consultants. David has 30 years of experience with expertise in endoscopic and surgical imaging, vast involvement at the local and national levels in quality assurance,  pharmacology, and therapeutics. He is the  former governor of the American College of Gastroenterology,  National Patient Care Committee member, Anthem’s Pharmaceutical  and Therapeutics  Committee,  Yale GI Leadership Committee,  and served as a Yale ambulatory endoscopy director for more than a decade.  David is a Board certified gastroenterologist and prior emergency medicine physician.  He is a Fellow of the American Gastroenterology Association, American College of Gastroenterology, and Jonathan Edwards College of Yale University.  David is the recipient of the Vincent DeLuca Yale Teaching Award.

Sonia Sequeira has 12 years of experience in regulatory strategy, preclinical, CMC and early clinical development as a Head of IND and Product Development at the Memorial Sloan Kettering Cancer Center, New York and Vice President of Translational Science at the Y-mAbs Therapeutics, New York. She developed more than 70 Investigational New Drug Applications (IND) for small molecules, gene therapies, cell therapies, vaccines and antibodies currently in clinical development as well as theranostics and companion diagnostics, in both oncology and neurology. Sonia holds a PhD in Neuroscience and in Biochemistry from the University of Coimbra, Portugal and completed postdoctoral studies in Cellular Biochemistry and Biophysics at the Memorial Sloan Kettering Cancer Center.